The 2001 OxyContin black-box warning was a regulatory response to mounting concern about the drug’s abuse and diversion, but it did not itself close the widening gap between opioid-related harm and access to care. In the book’s account, the warning appears with a ten-point plan to curb abuse, and gains significance from the later history of a crisis that remained difficult to see—and was addressed unevenly across communities.

The Warning and the Abuse Response

The warning was issued in 2001. A contemporaneous Reuters report, dated July 25, described Purdue Pharma’s OxyContin as set to receive a black-box warning; the book’s notes also connect the warning to a ten-point plan to curb abuse. The available account does not enumerate the plan’s provisions or specify what wording the warning carried, so its significance rests here on the documented sequence: concern over OxyContin abuse and diversion prompted a formal response, while the drug remained part of a much larger and still-unfolding public-health story.

The warning followed a period when heroin in Roanoke had been understood principally through police and court reporting. In the 1980s and 1990s, the local group of heroin users was described as small, mostly African American, and socially isolated. Because use was often hidden from public view, many people understood heroin as an inner-city drug rather than a problem that could spread into suburban families. The later attention to prescription opioids and addiction unsettled that narrow picture, though the book does not treat the 2001 warning as an event that, by itself, transformed public understanding.

A Crisis That Remained Difficult to See

The book contrasts the warning’s regulatory visibility with the limited visibility of heroin use in Roanoke. The drug’s users were often perceived as withdrawn from public life, and the people who used or sold it were not necessarily producing the kinds of visible street crime that drew sustained attention. That relative invisibility helped leave heroin outside the region’s dominant understanding of drug problems even as opioid-related harms developed.

When reporting on heroin in the suburbs began in 2012, families were often too ashamed to speak publicly. Five years later, most were willing to be named, while some still feared consequences for their employment or safety. The change in willingness to speak shows how the crisis became more publicly recognizable; it does not establish that the black-box warning caused that change. Rather, the warning belongs to an earlier phase of formal action, while the later reporting records how slowly the human consequences became discussable.

Unequal Medical and Criminal Responses

The wider history also complicates any account of opioid control as a uniform response. In 2014, data from the Centers for Disease Control and Prevention showed that doctors prescribed painkillers to people of color at substantially lower rates than to white patients, in part because of mistrust and assumptions about misuse. By then, overdose deaths among young white people were three times their 2002 rate, while the death rate for people of color had changed relatively little. The book presents this disparity as a consequence of unequal prescribing, not as evidence of any inherent difference between groups.

The disparity in medical access existed alongside a disparity in criminal enforcement. The book contrasts repeated calls that society could not arrest its way out of the opioid problem with the continued imprisonment of people such as Ronnie Jones for heroin distribution. It describes drug enforcement and sentencing as falling disproportionately on Black and Hispanic people, even as many white opioid users who dealt drugs or committed property crimes to stave off withdrawal were discussed primarily through a public-health lens. The 2001 warning therefore sits within a larger account in which regulating a drug and treating people affected by addiction were distinct, and unequally distributed, forms of response.

Limits and Later Approaches

Later chapters show the practical barriers that a warning alone could not resolve. Jesse Bolstridge’s mother had already paid toward a costly rehabilitation stay, and Jesse had briefly received buprenorphine before being weaned off after three weeks. The National Institute on Drug Abuse’s director later argued that evidence supported long-term medication maintenance alongside behavioral treatment and recovery support, rather than short detoxification aimed at abstinence. This account does not make Jesse’s treatment history a direct consequence of the 2001 warning; it demonstrates how regulatory attention to drug abuse and the availability of effective, sustained care could remain separate matters.

By early 2017, the Hope Initiative was using a five-page spreadsheet listing thirty-six rehabilitation and aftercare providers to match people with services according to cost and bed availability. Volunteers also helped arrange outpatient medication-assisted treatment, though some disagreed about treating addiction with medication. Meanwhile, overdose calls involving fentanyl were arriving at twice the rate of the previous year. These later efforts reveal the scale of the work required beyond a warning: finding a bed, navigating eligibility and expense, and connecting a person to continuing treatment. The book presents the black-box warning as one documented intervention in a long crisis, not as a resolution to the conditions that allowed addiction and unequal responses to persist.